Inotek is focused on bringing potentially sight-saving therapies to patients at risk.

Our most advanced product candidate, trabodenoson, was previous being developed both as a monotherapy and as a fixed-dose combination with latanoprost, a leading glaucoma treatment. We have also previously investigated the potential for trabodenoson to directly protect retinal ganglion cells from damage, aiding in the fight against vision loss. In July 2017, the company announced the top-line results of Phase 2 fixed-dose combination trial of trabodenoson and latanoprost for the treatment of glaucoma. The trial did not meet its primary efficacy endpoint, and the company has since discontinued development of trabodenoson in order to focus on evaluating strategic alternatives.